ПРОФИЛАКТИКА И ЛЕЧЕНИЕ ИШЕМИЧЕСКИ-РЕПЕРФУЗИОННЫХ ПОВРЕЖДЕНИЙ ПРИ ТРАНСПЛАНТАЦИИ ПЕЧЕНИ – ВОЗМОЖНЫЙ ПУТЬ К РАСШИРЕНИЮ ДОНОРСКОГО ПУЛА
https://doi.org/10.15825/1995-1191-2013-3-102-114
Аннотация
Дефицит донорских органов индуцирует поиск альтернативных путей увеличения донорского пула. Од- ним из таковых является расширение критериев маргинального донора. Применение трансплантатов печени от доноров данной группы сопряжено с высоким риском развития ранней дисфункции транс- плантата, в основе которого лежит ишемически-реперфузионное повреждение (ИРП) печени. В связи с этим в обзоре рассмотрены основные этапы патогенеза ИРП печени, а также современные методы его профилактики и лечения.
Об авторах
Д. Л. Цой
Отделение трансплантации почки и печени (зав. – проф. Я.Г. Мойсюк ) ФГБУ «ФНЦ трансплантологии и искусственных органов им. акад. В.И. Шумакова» Минздрава России (директор – академик РАМН, проф. С.В. Готье), Москва, Российская Федерация
Россия
Россия
Я. Г. Мойсюк
Отделение трансплантации почки и печени (зав. – проф. Я.Г. Мойсюк ) ФГБУ «ФНЦ трансплантологии и искусственных органов им. акад. В.И. Шумакова» Минздрава России (директор – академик РАМН, проф. С.В. Готье), Москва, Российская Федерация
Кафедра трансплантологии и искусственных органов (зав. – академик РАМН, проф. С.В. Готье), ГБОУ ВПО «Первый МГМУ им. Сеченова» (ректор – член-корр. РАМН, проф. П.В. Глыбочко), Москва, Российская Федерация
Россия
Россия
Список литературы
1. US Department of Health and Human Services. Organ Procurement and Transplantation Network, http://optn. transplant.hrsa.gov/data/(2012).
2. Farmer D.G., Amersi F., Kupiec-Weglinski J.W. Current status of ischemia and reperfusion injury in the liver. Transplant Review. 2000; 14: 106.
3. Fondevila C., Busuttil R.W., Kupiec-Weglinski J.W: He- patic ischemia/reperfusion injury – a fresh look. Experi- mentaland Molecular Pathology. 2003; 74: 86.
4. Gao W., Bentley R.C., Madden J.F. Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation. Hepatology. 1998; 27: 1652.
5. Lentsch A. B., Kato A., Yoshidome H., McMasters K.M. & Edwards M.J. Inflammatory mechanisms and therapeu- tic strategies for warm hepatic ischemia/reperfusion in- jury. Hepatology. 2000; 32: 169–173.
6. Pannen B.H. New insights into the regulation of hepatic blood flow after ischemia and reperfusion. Anesthesia and Analgesia. 2002; 94: 1448–1457.
7. Serracino-Inglott F., Virlos I.T., Habib N.A. Differential nitric oxide synthase expression during hepatic ische- mia-reperfusion. American Journal of Surgery. 2003; 185: 589–595.
8. Scommotau S., Uhlmann D., Loffler B.M. Involvement of endothelin/nitric oxide balance in hepatic ischemia/ reperfusion injury. Langenbecks Archive Surgery. 1999; 384: 65–70.
9. Uhlmann D., Armann B., Gaebel G. Endothelin A recep- tor blockade reduces hepatic ischemia/reperfusion injury after warm ischemia in a pig model. Journal Gastroin- testinal Surgery. 2003; 7: 331–339.
10. Jaeschke H. Reactive oxygen and mechanisms of in- flammatory liver injury. Journal Gastroenterology and Hepatology. 2000; 15: 718–724.
11. Zwacka R.M., Zhou W., Zhang Y. Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation. Nature Medicine. 1998; 4: 698–704.
12. Zhou W., Zhang Y., Hosch M.S. Subcellular site of super- oxide dismutase expression differentially controls AP-1 activity and injury in mouse liver following ischemia/ reperfusion. Hepatology. 2001; 33: 902–914.
13. Upadhya A.G., Harvey R.P., Howard T.K. Evidence of a role for matrix metalloproteinases in cold preservation injury of the liver in humans and in the rat. Hepatology. 1997; 26: 922–928.
14. Jaeschke H. Molecular mechanisms of hepatic ischemi- areperfusion injury and preconditioning. American Jour- nal of Physiology – Gastrointestinal and Liver Physiolo- gy. 2003; 284: 15–26.
15. Fan C., Zwacka R.M., Engelhardt J.F. Therapeutic ap- proaches for ischemia/reperfusion injury in the liver Journal of Molecular Medicine. 1999; 77: 577–592.
16. Pober J.S. Activation and injury of endothelial cells by cytokines. PathologieBiologie. 1998; 46: 159–163.
17. Shibuya H., Ohkohchi N., Tsukamoto S., Satomi S. Tumor necrosis factor-induced, superoxide-mediated neutrophil accumulation in cold ischemic/reperfused rat liver. He- patology. 1997; 26: 113–120.
18. Shito M., Wakabayashi G., Ueda M. Interleukin 1 re- ceptor blockade reduces tumor necrosis factor produc- tion, tissue injury, and mortality after hepatic ische- mia-reperfusion in the rat. Transplantation. 1997; 63: 143–148.
19. Ronald W. Busuttil and Koichi Tanaka. The Utility of Marginal Donors in Liver Transplantation. Liver Trans- plantation. 2003; 9: 651–663.
20. Workgroup on Expanded Criteria Organs for Liver Transplantation, New York State Department of Health Workgroup, 2005.
21. Francёois Durand, John F. Renz, Barbara Alkofer, Pa- trizia Burra, Pierre-Alain Clavien, Robert J. Porte, Ri- chard B. Freeman and Jacques Belghiti. Report of the Paris Consensus Meeting on Expanded Criteria Donors in Liver Transplantation, 2008.
22. Busquets J., Xiol X., Figueras J., Jaurrieta E., Torras J., Ramos E. The impact of donor age on liver transplantati- on: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation. 2001; 71: 1765–1771.
23. Popper H. Aging and the liver. Progress in Liver Disea- ses. 1986; 8: 659–683.
24. Jimenez R.C., Moreno G.E., Colina R.F., Palma C.F., Loinaz S.C., Rodriguez G.F. Use of octogenarian livers safely expands the donor pool. Transplantation. 1999; 68: 572–575.
25. Yersiz H., Shaked A., Olthoff K., Imagawa D., Shack- leton C., Martin P., Busuttil R.W. Correlation between donor age and the pattern of liver graft recovery after transplantation. Transplantation. 1995; 60: 790–794.
26. Adam R., Astarcioglu I., Azoulay D., Chiche L., Bao Y.M., Castaing D., Bismuth H. Liver transplantation from el- derly donors. Transplant Procurement. 1993; 25: 1556– 1557.
27. Ploeg R.J., D’Alessandro A.M., Knechtle S.J., Ste- gall M.D., Pirsch J.D., Hoffmann R.M. Risk factors for primary dysfunction after liver transplantation – a multi- variate analysis. Transplantation. 1993; 55: 807–813.
28. Piratvisuth T., Tredger J.M., Hayllar K.A., Williams R. Contribution of true cold and rewarming ischemia times to factors determining outcome after orthotopic liver transplantation. Liver Transplant Surgery. 1995; 1: 296– 301.
29. Verran D., Kusyk T., Painter D., Fisher J., Koorey D., Strasser S. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplan- tation. Liver Transplantation. 2003; 9: 500–505.
30. Urena M.A., Ruiz-Delgado F.C., Gonzalez E.M., Segu- rola C.L., Romero C.J., Garcia I.G. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transplant Procurement. 1998; 30: 3288–3291.
31. Fishbein T.M., Fiel M.I., Emre S., Cubukcu O., Guy S.R., Schwartz M.E. Use of livers with microvesicular fat sa- fely expands the donor pool. Transplantation. 1997; 64: 248–251.
32. McCormack L., Petrowsky H., Jochum W., Mullhaupt B., Weber M., Clavien P.A. Use of severely steatotic grafts in liver transplantation: a matched case-control study. An- nals of Surgery. 2007; 246: 940–946; 946–948.
33. Spitzer A.L., Lao O.B., Dick A.A. The biopsied donor liver: Incorporating macrosteatosis into high-risk donor assessment. Liver Transplantation. 2010; 16: 874–884.
34. Takeda Y., Arii S., Kaido T., Niwano M., Moriga T., Mori A. Morphologic alteration of hepatocytes and sinu- soidal endothelial cells in rat fatty liver during cold pre- servation and theprotective effect of hepatocyte growth factor. Transplantation. 1999; 67: 820–828.
35. Selzner M., R ̈uDiger H.A., Sindram D., Madden J., Cla- vien P-A. Mechanisms of ischemic injury are different in
36. the steatotic and normal rat liver. Hepatology. 2000; 32: 1280–1288.
37. Loinaz C., Gonzalez E.M. Marginal donors in liver transplantation. Hepatogastroenterology. 2000; 47: 256–263.
38. Canelo R., Braun F., Sattler B., Klinge B., Lorf T., Ramadori G. Is a fatty liver dangerous for transplantation?
39. Transplant Procurement. 1999; 31: 414–415.
40. Hubutia M.S., Gulyaev V.A., Zimina L.N., Novrusbe- kov M.S., Minina M.G. Comprehensive assesmesment of the liver after laparotomy in multiorgan donor. Vestnik transplantologii i iskusstvennyh organov. 2012; 12 (1): 41–49 (in rus).
41. Casavilla A., Ramirez C., Shapiro R., Nghiem D., Miracle K., Bronsther O. Experience with liver and kidney al- lografts from non-heart-beating donors. Transplantation. 1995; 59: 197–203.
42. Suarez F., Otero A. Solla M., Arnal F., Lorenzo M.J., Ma- rini M. Biliary complications after liver transplantation from Maastricht category-2 non-heart-beating donors. Transplantation. 2008; 85: 9–14.
43. Deshpande R., Heaton N. Can non-heart-beating donors replace cadaveric heart-beating liver donors? Journal of Hepatology. 2006; 45: 499–503.
44. Muiesan P., Girlanda R., Jassem W., Melendez H.V., O’Grady J., Bowles M. Single-center experience with liver transplantation from controlled non-heart beating donors: a viable source of grafts. Annals of Surgery. 2005; 242: 732–738.
45. Mateo R., Cho Y., Stapfer M. Risk factors for graft survi- val after liver transplantation from donation after cardiac death donors: An analysis of OPTN/UNOS data. Ameri- can Journal of Transplantation. 2006; 6: 791–796.
46. Fujita S., Mizuno S., Fujikawa T. Liver transplantation from donation after cardiac death: A single center expe- rience. Transplantation. 2007; 84: 46–49.
47. Seehofera D., Euricha D., Veltzke-Schliekera W., Neu- haus P. Biliary Complications After Liver Transplanta- tion: Old Problems and New Challenges. The American Society of Transplantation and the American Society of Transplant Surgeons. 2013: 253–254.
48. Feng S., Goodrich N.P., Bragg-Gresham J.L. Characte- ristics associated with liver graft failure: The concept of a donor risk index. American Journal of Transplantati- on. 2006; 6: 783–790.
49. Braata A.E., Bloka J. J., Putterb H., Adamc R., Bur- roughsd A. K., Rahmele A. O., Portef R. J., Rogiersg X., Ringersa J. The European Liver and Intestine Transplant Association (ELITA) and Eurotransplant Liver Intestine Advisory Committee (ELIAC). The Eurotransplant Do- nor Risk Index in Liver Transplantation: ET-DRI: The American Society of Transplantation and the American Society of Transplant Surgeons, 2012.
50. Moreno C., Sabate A., Figueras J. Hemodynamic profile and tissular oxygenation in orthotopic liver transplantati- on: influence of hepatic artery or portal vein revasculari- zation of the graft. Liver Transplantation. 2006; 12: 1607.
51. Sankary H.N., McChesney L., Frye E., Cohn S., Fos- ter P., Williams J. A simple modification in operative technique can reduce the incidence of nonanastomotic biliary strictures after orthotopic liver transplantation. Hepatology. 1995; 21: 63.
52. Massarollo P.C., Mies S., Raia S. Simultaneous arterial and portal revascularization in liver transplantation.
53. Transplant Procurement. 1998; 30: 2883.
54. Piratvisuth T., Tredger J.M., Hayllar K.A., Williams R. Contribution of true cold and rewarming ischemia times to factors determining outcome after orthotopic liver transplantation. Liver Transplant Surgery. 1995; 1: 296.
55. Platz K.P., Mueller A.R., Schafer C., Jahns S., Guckel- berger O., Neuhaus P. Influence of warm ischemia time on initial graft function in human liver transplantation. Transplant Procurement. 1997; 29: 3458.
56. Kniepeiss D., Iberer F., Grasser B., Schaffellner S., Stadlbauer V., Tscheliessnigg K.H. A single-center expe- rience with retrograde reperfusion in liver transplantation. Transplant International. 2003; 16: 730.
57. Daniela K., Michael Z., Florian I. Influence of retrogra- de flushing via the caval vein on the post-reperfusion syndrome in liver transplantation. Clinical Transplantation. 2004; 18: 638.
58. Heidenhain C., Heise M., Jonas S. Retrograde reperfusion via vena cava lowers the risk of initial nonfunction but increases the risk of ischemic-type biliary lesions in liver transplantation – a randomized clinical trial. Transplant International. 2006; 19: 738.
59. Brockmann J.G., August C., Wolters H.H. Sequence of reperfusion influences ischemia/reperfusion injury and primary graft function following porcine liver transplan- tation. Liver Transplantation. 2005; 11: 1214.
60. Schemmer P., Nickkholgh A., Hinz U. Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analy- sis. Transplant Procurement. 2007; 39: 529.
61. Prats N., Sans M., Piquґe J.M. Preconditioning protects against systemic disorders associated with hepatic ische- mia-reperfusion through blockade of tumor necrosis factor-induced P-selectin up-regulation in the rat. Hepa- tology. 2001; 33: 100–113.
62. Hardy K.J., McClure D.N., Subwongcharoen S. Ischa- emic preconditioning of the liver: a preliminary study. Australian and New Zealand Journal of Surgery. 1996; 66: 707–710.
63. Shcherba A.E., Korotkov S.V., Minov A.F., Slobodin Y.V., Savchuk M.M., Dzyadzko A.M., Rummo O.O. Impact of sevoflurane and acetilcysteini on ischemia-reperfusion ingury of the liver from brain-dead donor. Vestnik trans- plantologii i iskusstvennyh organov. 2013; 13 (1): 39–44 (in rus).
64. Cerwenka H., Bacher H., Werkgartner G., El-Shabra- wi A., Quehenberger F., Hauser H. Antioxidant treat- ment during liver resection for alleviation of ischemia – reperfusion injury. Hepatogastroenterology. 1998; 45: 777–782.
65. Kim Y.I., Fujita S., Hwang Y.J., Chun J.M., Song K.E., Chun B.Y. Successful intermittent application of the Pringle maneuver for 30 minutes during human hepate- ctomy: a clinical randomized study with use of a prote-
66. ase inhibitor. Hepatogastroenterology. 2007; 54: 2055–2060.
67. Sugawara Y., Kubota K., Ogura T., Esumi H., Inoue K., Takayama T. Protective effect of prostaglandin E1 against ischemia/reperfusion-induced liver injury: results of a prospective, randomized study in cirrhotic patients undergoing subsegmentectomy. Journal of He- patology. 1998; 29: 969–976.
68. Orii R., Sugawara Y., Hayashida M., Yamada Y., Chang K., Takayama T. Effects of amrinone on ischa- emia-reperfusion injury in cirrhotic patients undergo- ing hepatectomy: a comparative study with prostag- landin E1. British Journal of Anaesthesia. 2000; 85: 389–395.
69. Shirabe K., Takenaka K., Yamamoto K., Kitamura M., Itasaka H., Matsumata T. The role of prostanoid in hepa- tic damage during hepatectomy. Hepatogastroenterolo- gy. 1996; 43: 596–601.
70. Zhai Y., Busuttil R.W., Kupiec-Weglinski J.W. Liver Ischemia and Reperfusion Injury: New Insights into Me- chanisms of Innate – Adaptive Immune-Mediated Tissue Inflammation. American Journal of Transplantation. 2011; 11: 1563–1569.
71. Busuttil R.W., Lipshutz G.S., Kupiec-Weglinski J.W., Ponthieuxa S., Gjertsona D.W., Cheadle C., Watkins T., Ehrlich E., Katz E., Squiers E.C., Rabb H., Hemmeri- che S. rPSGL-Ig for Improvement of Early Liver Allo- graft Function: A Double-Blind, Placebo-Controlled, Single-Center Phase II Study. American Journal of Transplantation. 2011; 11: 786–797.
72. Sebastian Pratschke. Protocol TOP-Study (tacrolimus organ perfusion): a prospective randomized multicenter trial to reduce ischemia reperfusion injury in transplan- tation of marginal liver grafts with an ex vivo tacrolimus perfusion. Transplantation Research. 2013; 2: 3.
73. Straatsburg I.H., Abrahamse S.L., Song S.W., Hart- man R.J., Van Gulik T.M. Evaluation of rat liver apop- totic and necrotic cell death after cold storage using UW, HTK, and Celsior. Transplantation. 2002; 74: 458–464.
74. Chazouilleres O., Calmus Y., Vaubourdolle M., Ballet F. Preservation induced liver injury. Clinical aspects, me- chanisms and therapeutic approaches. Journal of Hepa- tology. 1993; 18: 123–134.
75. Upadhya G.A., Strasberg S.M. Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloprote- inases contained in University of Wisconsin and histidi- ne/tryptophan/ ketoglutarate liver preservation solutions. Hepatology. 2000; 31: 1115–1122.
76. Monbaliu D., Brassil J. Machine perfusion of the liver: Past, present and future. Current Opinion Organ Trans- plantation. 2010; 15: 160–166.
77. Butler A.J., Rees M.A., Wight D.G. Successful extracor- poreal porcine liver perfusion for 72 hr. Transplantation. 2002; 77: 1212–1218.
78. S. op den Dries. Ex vivo Normothermic Machine Perfu- sion and Viability Testing of Discarded Human Donor Livers. The American Society of Transplantation and the American Society of Transplant Surgeons, 2013.
Рецензия
Для цитирования:
Цой Д.Л., Мойсюк Я.Г. ПРОФИЛАКТИКА И ЛЕЧЕНИЕ ИШЕМИЧЕСКИ-РЕПЕРФУЗИОННЫХ ПОВРЕЖДЕНИЙ ПРИ ТРАНСПЛАНТАЦИИ ПЕЧЕНИ – ВОЗМОЖНЫЙ ПУТЬ К РАСШИРЕНИЮ ДОНОРСКОГО ПУЛА. Вестник трансплантологии и искусственных органов. 2013;15(3):102-114. https://doi.org/10.15825/1995-1191-2013-3-102-114
For citation:
Tsoy D.L., Moysyuk Y.G. PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION INJURY IN LIVER TRANSPLANTATION-POSSIBLE WAY TO EXPAND THE DONOR POOL. Russian Journal of Transplantology and Artificial Organs. 2013;15(3):102-114. (In Russ.) https://doi.org/10.15825/1995-1191-2013-3-102-114
Просмотров: 2641
Послать статью по эл. почте 